Loading...
•
Jun 30, 2022
Cardiff Oncology Q2 2022 Earnings Report
Reported second quarter results and provided business updates.
Key Takeaways
Cardiff Oncology reported its second quarter 2022 financial results, highlighting preclinical data in ovarian cancer and data from its Phase 2 metastatic castration-resistant prostate cancer clinical trial. The company had approximately $122 million in cash, cash equivalents, and short-term investments as of June 30, 2022.
Initial preclinical data in ovarian cancer presented at AACR showed treatment with onvansertib plus olaparib leading to a statistically significant survival benefit compared to treatment with either agent alone.
Data from Phase 2 metastatic castration-resistant prostate cancer (mCRPC) clinical trial presented at AACR showed higher disease control rates with increasing onvansertib dose density.
Biomarker data from Phase 2 mCRPC clinical trial presented at AACR showed treatment response correlating with mutations in MTOR and PTEN, two key genes in the PI3K signaling pathway.
Cash, cash equivalents, and short-term investments of approximately $122 million as of June 30, 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...